Supplementary Table and Figures: Table S1: Prostate cancer tumor microarray characteristics Fig. S1: IRS antibody validation Fig. S2: Effect of NT157 on the viability of benign prostatic cell line Fig. S3: Immunoblot analysis of cell cycle markers Fig. S4: NT157 inhibits LNCaP xenograft growth and delays CRPC Table S2: Growth rate calculation for NT157 treated xenografts Fig. S5: NT157 treatment of LNCaP Xenograft has no effect on mice body weight Fig. S6: NT157 potentiates docetaxel activity in PC3 xenografts Table S3: Growth rate calculation for NT157 and Docetaxel treated PCs xenografts Fig. S7: Growth rate calculation for NT157 and Docetaxel treated PCs xenografts Fig. S8: NT157 treatment of PC3 xenograft tumors has no effect on mice body weight